A2 Biotherapeutics is a developer of cell therapies for cancer, has raised $57M in Series A funding from The Column Group, Vida Ventures, Samsara BioCapital, and Nextech Invest. A2 Biotherapeutics was founded by Alexander Kamb in 2018 and has raised a total of $57M across two rounds.
The TechWatch Media Group audience is driving progress and innovation on a global scale. TechWatch Media is the highway for technology and entrepreneurship. There are a number of options to reach this audience of the world’s most innovative organizations and startups at scale including sponsoring a report like this. Find out more here.